Cytokinetics Inc Call to Discuss the Full Results from REDWOOD-HCM Transcript
Good afternoon, and welcome, ladies and gentlemen, to the Cytokinetics call announcing the full results of REDWOOD-HCM. At this time, I would like to inform you that this call is being recorded. (Operator Instructions)
I will now turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Welcome, everyone, and thanks for joining us this morning on the call today, focused on the full results of REDWOOD-HCM, the Phase II clinical trial of aficamten, our next-in-class cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathy, or HCM. Robert Blum, our President and Chief Executive Officer, will lead us off with an overview of yesterday's announcement. Then Fady Malik, our Executive Vice President of R&D, will discuss the next-in-class properties of aficamten and how it was designed to optimize clinical utility as could be assessed in a trial like REDWOOD-HCM.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |